LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-20 and is reviewed periodically as new material appears.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
=== Fatty liver disease === Studies in mice have shown that activation of FFAR3 by short-chain fatty acids (SC-FAs) suppresses liver lipid synthesis, reduces triglyceride accumulation, and decreases liver weight in models of diet-induced obesity. Mice lacking the Ffar3 gene fail to exhibit these protective effects, suggesting a critical role for FFAR3 in preventing excessive hepatic fat accumulation. These findings support further research to determine whether FFAR3 functions similarly in humans and whether FFAR3 activators could be developed as potential treatments for human fatty liver diseases, including non-alcoholic fatty liver disease.Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F (June 2016). "From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites". Cell. 165 (6): 1332–1345. doi:10.1016/j.cell.2016.05.041. PMID 27259147. S2CID 8562345.
Firstly, chemical reactions have been used to introduce tags into specific sites or proteins for the purpose of probing specific protein functionalities. The isolation of phosphorylated peptides has been achieved using isotopic labeling and selective chemistries to capture the fraction of protein among the complex mixture. Secondly, the ICAT technology was used to differentiate between partially purified or purified macromolecular complexes such as large RNA polymerase II pre-initiation complex and the proteins complexed with yeast transcription factor. Thirdly, ICAT labeling was recently combined with chromatin isolation to identify and quantify chromatin-associated proteins. Finally ICAT reagents are useful for proteomic profiling of cellular organelles and specific cellular fractions. Another quantitative approach is the accurate mass and time (AMT) tag approach developed by Richard D. Smith and coworkers at Pacific Northwest National Laboratory. In this approach, increased throughput and sensitivity is achieved by avoiding the need for tandem mass spectrometry, and making use of precisely determined separation time information and highly accurate mass determinations for peptide and protein identifications.
=== Banana equivalent dose === The origin of the concept of using a banana equivalent dose (BED) as a benchmark is unknown. In 1995, Gary Mansfield of the Lawrence Livermore National Laboratory found the Banana Equivalent Dose (BED) to be very useful in explaining radiation risks to the public. It is not a formally used dose. The banana equivalent dose is the dose of ionizing radiation to which a person is exposed by eating one banana. Bananas contain potassium. Natural potassium consists of 0.0117% of the radioactive isotope 40K (potassium-40) and has a specific activity of 30,346 becquerels per kilogram, or about 30 becquerels per gram. The radiation dose from eating a banana is about 0.1 μSv. The value of this reference dose is given as "1" and thus becomes the "unit of measurement" banana equivalent dose. Consequently, other radiation exposures can be compared to the consumption of one banana. For example, the average daily total radiation exposure of a person is 100 banana equivalent doses. At 0.17 mSv per year, almost 10 percent of natural radioactive exposure in Germany (an average of 2.1 mSv per year) is caused by the body's own (vital) potassium. The banana equivalent dose does not take into account the fact that no radioactive nuclide is accumulated in the body through the consumption of potassium-containing foods. The potassium content of the body is in homeostasis and is kept constant.
== Chemistry == Chemically, Parmotrema perlatum contains atranorin and chloroatranorin, alongside a predominant stictic acid chemosyndrome that includes stictic as a major secondary metabolite and smaller amounts of constictic acid and other related substances. Testing the medulla (the inner layer beneath the upper cortex) with spot tests results in K+ (yellow), KC−, and P+ (orange) reactions. The cortical layer, in contrast, is K+ (yellow), KC−, and P−. The secondary metabolites of Parmotrema perlatum have been studied using gas chromatography–mass spectrometry (GC–MS) and liquid chromatography–mass spectrometry (LC–MS/MS). The lichen produces several notable compounds, including orcinol, atraric acid, benzoic acid, 2,4-dihydroxy-3,6-dimethyl-, methyl ester, and palmitic acid, methyl ester. GC–MS analysis revealed the presence of orcinol (63%) and atraric acid (21%) in the methanol extract, while benzoic acid was predominant in the chloroform extract. The hexane extract contained significant amounts of benzoic acid, 2,4-dihydroxy-3,6-dimethyl-, methyl ester (62%). A more recent study using liquid chromatography-electrospray ionization-mass spectrometry/mass spectrometry as an analysis technique tentatively identified a total of twenty-five lichen products, including 5 depsides, 12 depsidones, 2 diphenyl ethers, 1 aromatic considered as possible artifact, 1 dibenzofuran, 1 carbohydrate, 1 organic acid, and 2 undefined compounds.
Sources: en.wikipedia.org
The role of yeast in winemaking is the most important element that distinguishes wine from fruit juice. In the absence of oxygen, yeast converts the sugars of the fruit into alcohol and carbon dioxide through the process of fermentation. The more sugars in the grapes, the higher the potential alcohol level of the wine if the yeast are allowed to carry out fermentation to dryness. Sometimes winemakers will stop fermentation early in order to leave some residual sugars and sweetness in the wine such as with dessert wines. This can be achieved by dropping fermentation temperatures to the point where the yeast are inactive, sterile filtering the wine to remove the yeast or fortification with brandy or neutral spirits to kill off the yeast cells. If fermentation is unintentionally stopped, such as when the yeasts become exhausted of available nutrients and the wine has not yet reached dryness, this is considered a stuck fermentation. The most common yeast associated with winemaking is Saccharomyces cerevisiae which has been favored due to its predictable and vigorous fermentation capabilities, tolerance of relatively high levels of alcohol and sulfur dioxide as well as its ability to thrive in normal wine pH between 2.8 and 4. Despite its widespread use which often includes deliberate inoculation from cultured stock, S. cerevisiae is rarely the only yeast species involved in a fermentation. Grapes brought in from harvest are usually teeming with a variety of "wild yeast" from the Kloeckera and Candida genera.
An integral component of the Mannich reaction, in addition to an amine and a carbonyl compound, is a carbanion, which plays the role of the nucleophile in the nucleophilic addition to the ion formed by the reaction of the amine and the carbonyl.
== External links == "Erythropoietin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 7 April 2020. Overview of all the structural information available in the PDB for UniProt: P01588 (Erythropoietin) at the PDBe-KB.
Wright's invention did not lead to any further developments, and diamorphine became popular only after it was independently re-synthesized 23 years later by chemist Felix Hoffmann. Hoffmann was working at Bayer pharmaceutical company in Elberfeld, Germany, and his supervisor Heinrich Dreser instructed him to acetylate morphine with the objective of producing codeine, a constituent of the opium poppy that is pharmacologically similar to morphine but less potent and less addictive. Instead, the experiment produced an acetylated form of morphine one and a half to two times more potent than morphine itself. Hoffmann synthesized heroin on 21 August 1897, just eleven days after he had synthesized aspirin. The head of Bayer's research department reputedly coined the drug's new name of "heroin", based on the German heroisch which means "heroic, strong" (from the ancient Greek word "heros, ήρως"). Bayer scientists were not the first to make heroin, but their scientists discovered ways to make it, and Bayer led the commercialization of heroin. Bayer marketed diacetylmorphine as an over-the-counter drug under the trademark name Heroin. It was developed chiefly as a morphine substitute for cough suppressants that did not have morphine's addictive side-effects. Morphine at the time was a popular recreational drug, and Bayer wished to find a similar but non-addictive substitute to market. However, contrary to Bayer's advertising as a "non-addictive morphine substitute", heroin would soon have one of the highest rates of addiction among its users.
The electric charge per mole of elementary charges is a constant called the Faraday constant, F, whose value had been essentially known since 1834 when Michael Faraday published his works on electrolysis. In 1910, Robert Millikan obtained the first measurement of the charge on an electron, −e. The quotient F/e provided an estimate of the Avogadro constant. The classic experiment is that of Bower and Davis at NIST, and relies on dissolving silver metal away from the anode of an electrolysis cell, while passing a constant electric current I for a known time t. If m is the mass of silver lost from the anode and Ar the atomic weight of silver, then the Faraday constant is given by:
Sources: en.wikipedia.org
== Adverse effects == The most common adverse effects (≥5%) were somnolence and dry mouth. Lumateperone is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury.
=== Discovery === Copernicium was first created on 9 February 1996, at the Gesellschaft für Schwerionenforschung (GSI) in Darmstadt, Germany, by Sigurd Hofmann, Victor Ninov et al. This element was created by firing accelerated zinc-70 nuclei at a target made of lead-208 nuclei in a heavy ion accelerator. A single atom of copernicium was produced with a mass number of 277. (A second was originally reported, but was found to have been based on data fabricated by Ninov, and was thus retracted.)
=== Preliminary research === Mast cells have been suggested to play a role in a wide variety of additional conditions, with differing degrees of evidence. Cardiac mast cells (CMCs) in the human heart differ functionally from mast cells in other organs, and may be involved in both inducing and protecting against cardiovascular disease. They are suggested to play important roles in angiogenesis, atherosclerosis, fibrosis, and tissue regeneration. MCs are present in the nervous system, where they are known to interact with microglia, astrocytes, neurons, and endothelial cells, and may affect permeability of the blood-brain barrier. MCs may be involved in neurologic disorders such as migraine. MCs are suspected of playing a role in brain inflammation in disorders such as Alzheimer's disease, Parkinson's disease and Amyotrophic lateral sclerosis. A connection to neurodevelopmental problems in autism spectrum disorder (ASD) has also been suggested. In some areas the role of MCs is uncertain or is being reassessed. This includes autoimmune and inflammatory disorders involving the joints, muscles, and tendons such as rheumatoid arthritis, psoriatic arthritis, heterotopic ossification, and gout. In the gastrointestinal tract, mast cells communicate bidirectionally with neurons by producing histamine, serotonin and tryptase. Mast cell-neuron interactions may be linked to pain and inflammation in food allergies and irritable bowel syndrome (IBS). It appears that MCs affect the evolution of digestive system tumors.
Only at some distance does convection occur to carry heat to the bulb's envelope. The orientation of the filament influences efficiency. Gas flow parallel to the filament, e.g., a vertically oriented bulb with vertical (or axial) filament, reduces convective losses. The efficiency of the lamp increases with a larger filament diameter. Thin-filament, low-power bulbs benefit less from a fill gas, so are often only evacuated. Early light bulbs with carbon filaments also used carbon monoxide, nitrogen, or mercury vapor. However, carbon filaments operate at lower temperatures than tungsten ones, so the effect of the fill gas was not significant as the heat losses offset any benefits.
=== Selective pressure incorporation (SPI) method for production of alloproteins === There have been many studies that have produced protein with non-standard amino acids, but they do not alter the genetic code. These protein, called alloprotein, are made by incubating cells with an unnatural amino acid in the absence of a similar coded amino acid in order for the former to be incorporated into protein in place of the latter, for example L-2-aminohexanoic acid (Ahx) for methionine (Met). These studies rely on the natural promiscuous activity of the aminoacyl tRNA synthetase to add to its target tRNA an unnatural amino acid (i.e. analog) similar to the natural substrate, for example methionyl-tRNA synthase's mistaking isoleucine for methionine. In protein crystallography, for example, the addition of selenomethionine to the media of a culture of a methionine-auxotrophic strain results in proteins containing selenomethionine as opposed to methionine (viz. Multi-wavelength anomalous dispersion for reason). Another example is that L-photo-leucine and photomethionine are added instead of leucine and methionine to cross-label protein. Similarly, some tellurium-tolerant fungi can incorporate tellurocysteine and telluromethionine into their protein instead of cysteine and methionine. The objective of expanding the genetic code is more radical as it does not replace an amino acid, but it adds one or more to the code. On the other hand, proteome-wide replacements are most efficiently performed by global amino acid substitutions.
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.